Stocktoria
Neuraxis, INC NRXS
NYSE American · XASE · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2023-08-09
Neuraxis, INC statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 84.2% | 86.5% | 87.7% | 88.9% |
| Operating margin | -219.4% | -266.5% | -270.9% | -125.6% |
| Net margin | -218.5% | -306.8% | -594.6% | -178.0% |
| FCF margin | -181.1% | -228.1% | -273.4% | -85.6% |
| Return on assets | -121.8% | -173.2% | -2870.8% | -322.8% |
| Return on equity | -229.5% | -398.6% | 1042.4% | 85.8% |
| Debt / equity | — | — | — | -0.04× |
| Current ratio | 2.05 | 1.75 | 0.13 | 0.07 |
Source: SEC EDGAR filings · CIK 0001933567 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.